Claritev Corporation
NYSE:CTEVMedical - Healthcare Information Services
+$0.42 today
- Market cap
- $380.77M
- Beta
- 0.77
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$17.16
Volume 0.31M
Average 0.14M
CTEV Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Claritev CorporationNYSE: CTEV
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital growth accelerates
Q1 FY2026 change in working capital of $79.97M (cash outflow) rose 101.2% year over year, ahead of the -1.0% change in trailing-twelve-month change in working capital.
Context
- Change in working capital amounted to 3.0% of revenue in FY2025, up 1.5 pp from a year earlier.
- Change in working capital increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +101.2% holds above the trailing-twelve-month pace of -1.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (28.87M) USD
- Year-over-year change
- -111.2%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (28.87M) | -111.2% |
| FY2024 | 2024-12-31 | (13.67M) | +37.6% |
| FY2023 | 2023-12-31 | (21.91M) | -139.6% |
| FY2022 | 2022-12-31 | 55.34M | +218.5% |
| FY2021 | 2021-12-31 | (46.68M) | — |
Change in Working Capital vs competitors
How CTEV compares with its peers on the latest reported figures
- CTEV's LTM Mar 2026 change in working capital of $69.09M is the largest of the 11 companies compared; the peer median is $14.21M.
- Its year-over-year change of -1.0% is the 7th highest of 11, against a peer median of +49.7%.
- Change in working capital amounts to 7.1% of revenue for CTEV, versus a peer median of 3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
CTEVClaritev Corporation | LTM Mar 2026 | $69.09M | -1.0% | — | 7.1% |
| LTM Mar 2026 | $45.87M | -54.7% | -18.1% | 2.4% | |
| LTM Mar 2026 | $42.39M | -9.2% | +40.6% | 5.4% | |
| LTM Mar 2026 | $39.86M | +94.5% | — | 6.9% | |
| LTM Mar 2026 | $39.71M | +198.8% | -5.1% | 2.4% | |
| LTM Mar 2026 | $20.31M | +46.8% | +75.8% | 5.4% | |
| LTM Jun 2026 | $12.54M | +251.7% | — | 658.7% | |
| LTM Sep 2026 | $8.1M | -48.9% | +37.1% | 3.0% | |
| LTM Mar 2026 | $6.99M | +52.5% | — | — | |
| LTM Mar 2026 | $4.9M | +273.5% | +71.8% | 2.2% | |
| LTM Mar 2026 | $1.44M | -133.6% | -4.9% | 1.7% | |
| Peer median (excluding CTEV) | $14.21M | +49.7% | +37.1% | 3.0% | |
Competitors are the stored peer set for CTEV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 102.08M | (572.91M) | (91.7M) | (1.65B) | (284.28M) |
| Depreciation & Amortization | 424.32M | 415.66M | 425.79M | 436.44M | 445.43M |
| Deferred Income Tax | (81.93M) | (114.38M) | (114.06M) | (198.01M) | (128.51M) |
| Stock-Based Compensation | 18.01M | 16.74M | 18.02M | 26.65M | 27.82M |
| Change in Working Capital | (46.68M) | 55.34M | (21.91M) | (13.67M) | (28.87M) |
| Accounts Receivables | (33.83M) | 21M | 4.4M | (13.2M) | (26.57M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 7.71M | 34.35M | 5.58M | 42.22M | (25.86M) |
| Other Working Capital | (12.85M) | 34.34M | (26.31M) | (42.69M) | 23.57M |
| Other Non-Cash Items | (93.04M) | 571.92M | (44.42M) | 1.5B | 85.73M |
| Operating Cash Flow | 404.69M | 372.36M | 171.72M | 107.62M | 117.32M |
| Capital Expenditures | (84.59M) | (89.74M) | (108.85M) | (118.12M) | (129.6M) |
| Acquisitions (Net) | (149.43M) | 0 | (140.94M) | 0 | 0 |
| Purchases of Investments | 0 | (15M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 289K | 0 | 0 | 16M |
| Other Investing Activities | 5.64M | 0 | 0 | 0 | (7.42M) |
| Investing Cash Flow | (228.38M) | (104.45M) | (249.79M) | (118.12M) | (121.02M) |
| Debt Repayment | (10.9M) | (13.28M) | (165.82M) | (28.07M) | 4.72M |
| Common Stock Issued | 0 | 0 | 508K | 0 | 1.74M |
| Common Stock Repurchased | (103.79M) | (100M) | (15.22M) | (10.37M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.79M) | (2.46M) | (465K) | (2.88M) | (4.1M) |
| Financing Cash Flow | (114.68M) | (115.74M) | (180.99M) | (41.32M) | 2.36M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 61.62M | 152.18M | (259.07M) | (51.82M) | (1.33M) |
| Free Cash Flow | 320.1M | 282.63M | 62.87M | (10.51M) | (12.28M) |
Claritev Corporation
NYSE:CTEV
Intrinsic Alpha fair value
Locked
Current Price
$22.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.